Neil McKeganey is director of the Center for Substance Use Research in Glasgow, Scotland, and a frequent contributor to Tobacco Reporter. In this section, we feature a selection of his work.
A Missed Opportunity
Vaping firms should pay more attention to older smokers, argue Neil McKeganey, Gabe Barnard and Andrea Patton.
A Risky Strategy
Banning e-liquid flavors may not achieve the outcomes that proponents of that measure have in mind.
Show Them the Numbers
Manufacturers must show the benefit of pouches and quantify underage usage.
The Risk of an Own Goal
Making e-cigarettes available only on prescription may be a net negative for public health, writes Neil McKeganey.
A Ban By Any Other Name
FDA’s reluctance to permit flavors may hinder conversions to less harmful products.
Dropping Names
After rooting out ENDS flavors, regulators may turn their attention to flavor names, writes Neil McKeganey.
Logic Rejection Based on Fuzzy Math
The FDA used questionable statistics to justify its marketing denial, says Neil McKeganey.
A Second Chance
Neil McKeganey explains how companies can make the most of a recent ruling forcing the FDA to reconsider MDOs.
Scientists denounce ‘McCarthyism’
Neil McKeganey and Christopher Russell of the Centre for Substance Use Research in Glasgow, Scotland, have cautioned against a “new McCarthyism” in the area of e-cigarette research.
